In May 2017, Nevro CEO Rami Elghandour chatted with Anne Staylor, BioMedGPS Managing Editor/Neuro Analyst to discuss dynamics in the global spinal cord stimulation (SCS) market, including trends, drivers, challenges, competition, and opportunity that would influence the Company’s growth. 

A fascinating read then, that now has us appraising a year later if Elghandour's expansion predictions came to pass. Is Nevro still the one to beat as the top leader in the neuromodulation field?

 or read the interview in full below!

Medtronic’s Stacey Pugh discusses the Company’s new Riptide Aspiration System, new products in development, and growth strategies for the neurovascular business in a podcast interview with SmartTRAK at the International Stroke Conference (ISC) 2018 held Jan. 24-26, 2018 in Los Angeles, CA.

Anne Staylor here with BioMedGPS. We're at the International Stroke Conference in Los Angeles, and today I'm talking with Stacey Pugh of Medtronic Neurovascular. Hi Stacey, thanks for joining me.

In the market for stroke devices, Europe seems to be the proving ground for next generation devices, and several companies with novel technologies are emerging from Europe that could potentially reach the US market in the next several years. One European company taking aim at the US market is Bochum, Germany-based phenox GmbH.

SmartTRAK is excited to be attending LINNC Paris 2018 on June 11-13, 2018, at the Carrousel du Louvre, Paris, France.

The US Spinal Cord Stimulation market reached new heights in Q417/FY17, driven by new products, expanding indications, and a growing demand for non-narcotic alternatives for treating chronic intractable pain. 

Among the many topics covered in the Q417/FY17 Spinal Cord Stimulation Market Recap are:

Scott Drees, CEO of Nuvectra Corporation, discusses the Company’s challenges and opportunities in 2017, strategies for driving growth and market penetration in neuromodulation, and the Company’s key priorities for 2018 in an interview with SmartTRAK at the North American Neuromodulation Society Annual Meeting held Jan. 11-14, 2018 in Las Vegas, NV.

A transcript of SmartTRAK’s interview with Scott Drees is below, or click the following video to view the interview recorded live at NANS 2018. (17:41 minutes.)

SmartTRAK is excited to be attending #ISC 2018 - International Stroke Conference, January 24-26 at the Los Angeles Convention Center.

The International Stroke Conference is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease.

Kas Amirdelfan, MD talked with SmartTRAK at the ASRA 2017 Annual Meeting regarding preliminary 12 month results from the SENZA-ULN study

Kas Amirdelfan, MD, principle investigator of the SENZA-Upper Limb and Neck (ULN) study, spoke with SmartTRAK's Anne Staylor at the recent American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting in Lake Buena Vista, FL regarding preliminary 12 month results from SENZA-ULN, the unmet clinical need for chronic intractable ULN pain, factors affecting physician adoption for this indication and what’s next for this research. (See ASRA Poster 4194.) 

A transcript of SmartTRAK’s interview with Dr. Amirdelfan is below or click on the following video to view the interview recorded live at ASRA 2017. (13:23 minutes.)

SmartTRAK is excited to be attending NANS 2018 - the North American Neuromodulation Society's 21st Annual Meeting meeting on Jan 11-14, 2018 at Caesars Palace in Las Vegas, Nevada.

Fast Growing Spinal Cord Stim Market Slows in Q317 

While the overall Neuromodulation Spinal Cord Stimulation (SCS) market continues to see strong, double-digit growth YTD, sequentially the US SCS market decelerated in Q317 due to seasonality and hurricane-related supply chain disruptions, particularly affecting Medtronic.

By Anne Staylor, Managing Editor, SmartTRAK Business Intelligence

YTD, the US SCS market is trending at high growth rates, a faster growth than SmartTRAK’s original 2017 forecast, as next generation products continue to drive unprecedented growth in this highly underpenetrated market. In the US, Abbott, Nevro and Boston Scientific’s (BSX) Q317 YoY SCS revenues increased  respectively, while competitive pressures  accelerated Medtronic’s US SCS revenue decline, down YoY according to SmartTRAK Financial Dashboard.